News for QIAGEN N.V. (QIAN.MX)

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at where Qiagen N.V.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringeme

Qiagen stock faces market pressure due to recent NIH funding concerns, despite strong financials and a diverse product portfolio. Click to read why QGEN is a Hold.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Operator: Ladies and gentlemen, thank you for standing by. I am Taryn, your Global Meet call operator. Welcome, and thank you for joining the Q4 2024 earnings conference call webcast.

Qiagen N.V. (NYSE:QGEN) Q4 2024 Earnings Conference Call February 6, 2025 10:00 AM ETCompany ParticipantsJohn Gilardi – Vice President, Head of Corporate...

The following slide deck was published by Qiagen N.V.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shar

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) syste

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cancer Cell Analysis...

The immunoassay market is set for robust growth, projected to expand from USD 35.12 billion in 2023 to USD 54.27 billion by 2031, at a CAGR of 5.59%. Key...